$11.21
0.050.45%
Last update: Oct 23, 7:57 PM
Intellia Therapeutics Inc (NTLA) Stock Price, Quote, News & History
NTLANASDAQ
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
You can purchase shares of Intellia Therapeutics (NASDAQ:NTLA) through any online brokerage.
Other companies in Intellia Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Intellia Therapeutics has a consensus price target of $24.69.
The stock price for Intellia Therapeutics (NASDAQ: NTLA) is $11.1 last updated October 23, 2026 at 7:57 PM EDT.
There are no upcoming dividends for Intellia Therapeutics.
Intellia Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Intellia Therapeutics.
Intellia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a...
